Management of HBV infection in Japan

Minami, Masahito; Okanoue, Takeshi

doi:10.1111/j.1872-034x.2007.00109.x

Cited by 12 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Japanese multicenter collaborative trial of sequential therapy following a similar method to Saferty et al . also found no significant enhancement of therapeutic efficacy in comparison to IFN monotherapy as a historical control . However, this study did show that in almost all responders, HBeAg negative conversion occurred during initial lamivudine monotherapy.…”

Section: Pharmacotherapy (2) – Nascontrasting

confidence: 59%

JSH Guidelines for the Management of Hepatitis B Virus Infection

2014

Hepatology Research

137

View full text Add to dashboard Cite

Section: Pharmacotherapy (2) – Nascontrasting

confidence: 59%

JSH Guidelines for the Management of Hepatitis B Virus Infection

2014

Hepatology Research

137

View full text Add to dashboard Cite

“…Sequential lamivudine and interferon therapy induced less viral resistance to lamivudine than lamivudine monotherapy and appeared to have a better biochemical response than interferon or lamivudine monotherapy. The sequential administration of lamivudine and interferon can reduce treatment duration of each drug, resulting in less chance of viral resistance for lamivudine and less side effects from interferon [28].…”

Section: Discussionmentioning

confidence: 99%

Interferon and nucleoside analog combination therapy for hepatitis B

Minami

Katayama

Sendo

et al. 2010

Clin J Gastroenterol

Self Cite

View full text Add to dashboard Cite

Interferon therapy has several advantages over nucleoside or nucleotide analog therapy: finite duration, durable treatment response, and no viral resistance. However, it is only effective in about 30% of patients. To improve its efficacy, the combination of interferon and nucleoside/nucleotide analogs may facilitate additive or synergistic effects. This is because interferon and nucleoside/nucleotide analogs have different mechanisms of action. Recent studies demonstrate that concomitant use of lamivudine and peginterferon does not improve biochemical and virological responses compared with peginterferon monotherapy. By contrast, sequential or staggered administration of lamivudine and interferon appears to have some benefits over monotherapies. There is a paucity of data on interferon combined with drugs other than lamivudine, such as adefovir and entecavir. Although combination therapies have the potential to improve efficacy against hepatitis-B virus, it is unclear how interferon should be combined with other drugs or which patients should be treated with combination therapies.

show abstract

“…However, sequential entecavir and IFN therapy does not show evidence of superior therapeutic effects. Some studies of lamivudine and IFN sequential therapy indicated that the biochemical and virological responses were comparable or superior to lamivudine or interferon monotherapies [29,30], but no consistent assessment of the therapy exists. For young HBeAg-negative patients with HBV DNA of less than 7 log copies/ml, observation over time as a basic principle is generally considered acceptable, but in patients with intermittent ALT levels of at least 31 IU/ml, long-term IFN administration is recommended.…”

Section: Treatment Guidelines For Chronic Hepatitis Bmentioning

confidence: 98%

Current treatment for chronic hepatitis B in Japan

Ohishi

Chayama

2009

Clin J Gastroenterol

View full text Add to dashboard Cite

To standardize diagnosis, treatment, and management of chronic hepatitis B, updated treatment guidelines in Japan have been formulated by a research team of the Japanese Ministry of Health, Labor and Welfare (MHLW)'s study project "Research on standardization of treatment for viral liver diseases including liver cirrhosis." The guidelines recommend first that chronic hepatitis B patients characterized by ALT levels of at least 31 IU/l, with HBe antigen (HBeAg)-positive patients having HBV DNA levels of at least 5 log copies/ml and HBeAg-negative patients with HBV DNA levels of at least 4 log copies/ml, be targeted for treatment. Patients indicated for treatment intervention, for whom are suggested such basic treatments as entecavir therapy, long-term interferon (IFN) therapy, and sequential therapy, are divided into age groups comprising young patients (less than 35 years of age) and middle-aged/elderly patients (35 years and older), HBeAg-positive and HBe-negative patients, and patients with HBV DNA levels of at least 7 log copies/ml and those of less than 7 log copies/ml. As for switching to entecavir for chronic hepatitis B patients currently undergoing lamivudine therapy, the guidelines suggest specific therapies for different groups, dividing patients into those undergoing lamivudine therapy for less than 3 years and those treated for 3 years or longer, as well as those having HBV DNA levels of less than 1.8 log copies/ml and those of 1.8 log copies/ml or more. Formulated on the basis of consideration of chronic hepatitis B patient age, ALT level, HBeAg status, HBV DNA level, and liver disease severity, these guidelines are considered useful for the understanding and implementation of chronic hepatitis B infection diagnosis and treatment, which in recent years have advanced markedly and grown ever more diverse.

show abstract

Management of HBV infection in Japan

Cited by 12 publications

References 8 publications

JSH Guidelines for the Management of Hepatitis B Virus Infection

JSH Guidelines for the Management of Hepatitis B Virus Infection

Interferon and nucleoside analog combination therapy for hepatitis B

Current treatment for chronic hepatitis B in Japan

Contact Info

Product

Resources

About